MOLRECORD
PAPER SUMMARY PAPER Metabolic and the GLP-1 class

What GLP-1 users do differently: activity, bone and persistence

Three 2026 reports on behaviour and long-term signals outside the pivotal trials.

Published 5 Oct 2026 Event Mar – Jun 2026 Sources 3 EVIDENCE · OBSERVATIONALSOURCES · 3 REPORTSSTATUS · ABSTRACTS AND ONE JOURNAL PAPER
REPORTS
3
DESIGN
Observational
PERSISTENCE 2024
60.9 %
STATUS
Mixed

What was done

At ENDO 2026 (13 June) a study presented physical-activity data from adults with obesity losing weight on GLP-1 receptor agonists. At the AAOS 2026 annual meeting (2 March) a retrospective cohort study used a national claims database to examine GLP-1 use around ten common orthopaedic procedures from 2010 to 2023. A paper in the Journal of Managed Care & Specialty Pharmacy analysed persistence and adherence among people starting high-potency, weight-loss-indicated GLP-1 drugs from 2021 to the first half of 2024. [1][2][3]

What was found

Physical activity fell significantly among people losing weight on the drugs, which the authors flag because the drugs reduce lean mass as well as fat. The claims analysis associated long-term use with higher rates of osteoporosis, gout and osteomalacia alongside some short-term post-operative benefits. One-year persistence rose from 33.2 % in 2021 to 60.9 % in 2024, still below the levels seen in randomised trials. [1][2][3]

Limits

Two of the three are conference presentations, not peer-reviewed papers. The claims analysis is observational and cannot establish cause. The persistence cohort was younger, healthier and three-quarters female. [2][3]

Funding

To be added per report.

SOURCES

  1. Endocrine Society. Exercise decreases among people taking GLP-1 medication. ENDO 2026 press release, 13 Jun 2026. Conference abstract. https://www.endocrine.org/news-and-advocacy/news-room/2026/maharjan-press-release-endo-2026
  2. AAOS 2026 Annual Meeting. Studies explore GLP-1 receptor agonist use and its impact on long-term musculoskeletal health. 2 Mar 2026. Conference abstract. https://aaos-annualmeeting-presskit.org/2026/research-news/studies-explore-glp-1-receptor-agonist-use-and-its-impact-on-long-term-musculoskeletal-health/
  3. J Manag Care Spec Pharm. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated GLP-1 receptor agonists. 2026;32(3):281. Peer-reviewed. https://www.jmcp.org/doi/10.18553/jmcp.2026.32.3.281

CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN